A new drug that slows the pace of Alzheimer's disease is too expensive for too little benefit to be used on the NHS, the drugs spending watchdog says. Donanemab was hailed as a turning point in the disease last year.

A wife whose husband will not be eligible for new Alzheimer’s drugs has implored health leaders to ensure that others like him will be able to access treatments. New disease-modifying Alzheimer’s drugs work best when they are given to patients in the early stages of disease.

The most effective drug for Alzheimer’s will be blocked for use on the NHS on Wednesday. Regulators are expected to declare the new treatment for the disease safe for use but the rationing body for the health service will immediately rule that it is too expensive for NHS patients.

Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify the price.

Eli Lilly's treatment for early Alzheimer's was deemed too expensive for wide use by UK's cost-effectiveness body on Wednesday, signalling that patients are unlikely to get access following approval by the country's medicines regulator.

The U.K. watchdog declines to endorse Eli Lilly's Alzheimer's drug donanemab, citing lack of value for the NHS and taxpayers.

A new Alzheimer’s drug has been rejected for widespread use in the health service in England after the health spending watchdog said it “does not currently demonstrate value for the NHS”. The news comes as the UK’s medicines regulator said donanemab could be licensed for use in the UK.

UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's disease, the company said on Wednesday. Britain is the third major market where donanemab,

Donanemab has been hailed as 'game changer' but it's likely the price tag will bar it from being available to nearly one million Brits.